江南化工(002226.SZ):在新疆區域工業炸藥及製品生產許可能力從2019年末的7萬噸,大幅增長至2023年末的17萬噸
格隆匯5月10日丨江南化工(002226.SZ)在投資者互動平台表示,公司工業炸藥許可產能數據請以公司定期報吿披露為準。公司在新疆區域工業炸藥及製品生產許可能力從2019年末的7萬噸,大幅增長至2023年末的17萬噸,在新疆區域擁有較大的市場競爭力。內部,公司將發揮區域佈局優勢,按照工信部要求,公司產能可以動態調整,用於盤活閒置產能以實現產能效益最大化。外部,公司將積極響應《“十四五”民用爆炸物品行業安全發展規劃》要求,進一步加快產業重組整合、聯優並強,優化產能佈局、產品結構。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.